Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025206 · ClinicalTrials.gov registry record · Phase 1
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma
A Phase 1 study, sponsored by BioInvent International AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01025206 is a Phase 1 study that has completed, run by BioInvent International AB. The registered enrollment target is 35 participants.
The verdict
NCT01025206, a Phase 1 study, has completed, sponsored by BioInvent International AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.
Interventions
- BIOLOGICAL BI-505
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01025206
The ClinicalTrials.gov registry entry for NCT01025206 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioInvent International AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI-505 is the first listed.
NCT01025206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01025206 about?
NCT01025206 is a clinical study titled "A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma". This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.
What is the current status of trial NCT01025206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2009-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01025206?
The interventions under investigation include: BI-505 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01025206?
This trial is sponsored by BioInvent International AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.